Robert A. Figlin, MD, FACP, is the Steven Spielberg Family Chair in hematology/oncology, professor of medicine and biomedical sciences; director of the division of hematology/oncology; deputy director of the Samuel Oschin Comprehensive Cancer Institute; and deputy director of the integrated oncology service line at Cedars-Sinai Medical Center in Los Angeles, California.
Prior to joining Cedars-Sinai, Dr. Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the associate director for clinical research at the City of Hope Comprehensive Cancer Center. Prior to that, Dr. Figlin served as the Henry Alvin and Carrie L. Meinhardt endowed chair in urologic oncology and professor of medicine and urology in the divisions of hematology/oncology and urologic oncology at the David Geffen School of Medicine at UCLA, where he is emeritus professor of medicine.
Dr. Figlin is editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, JNCI, Lancet Oncology, and Journal of Urology. He has authored over 350 peer-reviewed articles, more than 70 book chapters, and has published multiple books in kidney cancer. He is the editor of the recently released book, Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets.
A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin’s research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the kidney cancer program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars-Sinai’s tradition of compassionate patient care.